Searched for
MODERNA VACCINE SALES
Moderna first-quarter revenue jumps on strong overseas COVID vaccine salesModerna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales. The company forecasts lower-tha...- Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.
- Moderna shares up 2% as skin cancer vaccine shows sustained benefit in five-year follow-upModerna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most dea...
- Moderna plans to lay off 10% of workforce to cut costsModerna is set to reduce its global workforce by roughly 10%, aiming for under 5,000 employees by year's end, as it accelerates cost-cuttin...
- Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sinkModerna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, which has los...
- Moderna pulls application for COVID-flu combination shotModerna has withdrawn its application for a combination flu and COVID vaccine, awaiting efficacy data from a late-stage influenza shot tria...
- Vaccine maker Moderna forecasts lower sales next year, shares tumble 17% to near four-year lowModerna has delayed its break-even goal by two years, pushing it to 2028, due to slower regulatory processes for key products like flu and ...
- GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technologyGlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech in Delaware federal court, alleging infringement of GSK's patents rel...
- Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts sayModerna, the COVID-19 vaccine manufacturer, is poised to meet its 2023 sales target as it taps into the private market. Analysts suggest th...
- Moderna to keep testing flu shot as it fails to meet 'early success' criteriaData from the second trial comes two months after its flu vaccine generated a strong immune response against influenza A strains, but was i...
- Johnson & Johnson suspends Covid vaccine sales forecastVaccine options from rival drugmakers Pfizer and Moderna have been much more commonly used so far in the United States, where overall vacci...
- WHO works to spread COVID vaccine technology to more nationsAt a press briefing in Geneva on Wednesday, WHO Director-General Tedros Adhanom Ghebreyesus said the new hub will be in South Korea and wil...
- Moderna finds that inventing a COVID-19 vaccine was the easy partModerna shares plummeted on Thursday after it announced it would be able to supply only 700 million to 800 million vaccine doses this year,...
- Moderna lowers forecast for 2021 COVID-19 vaccine deliveriesThe drugmaker said Thursday that longer delivery lead times for exports and a temporary impact from expanding its fill-finish capacity may ...
- Moderna COVID-19 vaccine tallies more than $4 billion in Q2 salesModerna's announcement comes after pharmaceutical giant Pfizer Inc. said its COVID-19 vaccine remained effective months after the second do...
- Moderna says its COVID-19 shot remains 93% effective 4-6 months after second doseThat compares favorably to data released by rivals Pfizer Inc and BioNTech SE last week in which they suggested their vaccine's efficacy wa...
- Johnson & Johnson forecasts $2.5 bn in Covid-19 vaccine sales this yearJ&J said it expects full-year sales of $91.3 billion-$92.1 billion this year from the rest of the business, and $93.8 billion to $94.6 bill...
- Moderna raises 2021 sales forecast for COVID-19 vaccine to $19.2 billionEarlier this week, larger rival Pfizer Inc said it expects $26 billion in sales of its COVID-19 vaccine this year.
- AstraZeneca has sold its stake in Moderna for more than $1 billion: The TimesAstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University COVID-19 vac...
- Moderna mania draws bitcoin comparisons while shorts bleedModerna jumped as much as 17% in New York Tuesday. The stock has surged about 73% and added more than $28 billion in market value over the ...
Load More
